帮助 关于我们

返回检索结果

Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study

查看参考文献23篇

文摘 Objective: To evaluate the association between Chinese medicine(CM) therapy and disease-free survival(DFS) outcomes in postoperative patients with non-small cell lung cancer(NSCLC). Methods: This multiple-center prospective cohort study was conducted in 13 medical centers in China. Patients with stage Ⅰ, Ⅱ, or ⅢA NSCLC who had undergone radical resection and received conventional postoperative treatment according to the National Comprehensive Cancer Network(NCCN) guidelines were recruited. The recruited patients were divided into a CM treatment group and a control group according to their wishes. Patients in the CM treatment group received continuous CM therapy for more than 6 months or until disease progression. Patients in the control group received CM therapy for less than 1 month. Follow-up was conducted over 3 years. The primary outcome was DFS, with recurrence/metastasis rates as a secondary outcome. Results: Between May 2013 and August 2016, 503 patients were enrolled into the cohort; 266 were classified in the CM treatment group and 237 in the control group. Adjusting for covariates, high exposure to CM was associated with better DFS [hazard ratio(HR) = 0.417, 95% confidential interval(CI): 0.307–0.567)]. A longer duration of CM therapy(6–12 months, 12–18 months, >24 months) was associated with lower recurrence and metastasis rates(HR = 0.225, 0.119 and 0.083, respectively). In a subgroup exploratory analysis, CM therapy was also a protective factor of cancer recurrence and metastasis in both stage Ⅱ–ⅢA(HR=0.50, 95% CI: 0.37–0.67) and stage ⅢA NSCLC postoperative patients(HR = 0.48, 95% CI: 0.33–0.71), DFS was even longer among CM treatment group patients. Conclusions: Longer duration of CM therapy could be considered a protective factor of cancer recurrence and metastasis. CM treatment is associated with improving survival outcomes of postoperative NSCLC patients in China.(Registration No. ChiCTR-OOC-14005398).
来源 Chinese Journal of Integrative Medicine ,2019,25(11):812-819 【核心库】
DOI 10.1007/s11655-019-3168-6
关键词 Chinese medicine ; non-small cell lung cancer ; postoperative care ; cohort study ; disease-free survival
地址

1. Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences, Beijing, 100053  

2. Department of Oncology,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510000  

3. Department of Oncology,Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, 410000  

4. Department of Integrated TCM & Western Medicine,Cancer Hospital of Liaoning Province, Shenyang, 110000  

5. Department of Traditional Chinese Medicine,Cancer Hospital of Shanxi Province, Taiyuan, 030000  

6. Department of Oncology,The Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Urumqi, 830000  

7. Department of Oncology,Zhejiang Province Traditional Chinese Medicine Hospital, Hangzhou, 310000  

8. Oncology Department of Traditional Chinese Medicine,Anhui Provincial Hospital, Hefei, 230000  

9. Oncology Department of Traditional Chinese Medicine,Chongqing Cancer Hospital, Chongqing, 400000  

10. Department of Oncology,Wuxi Hospital of Traditional Chinese Medicine, Jiangsu, Wuxi, 214000  

11. Department of Oncology,Dalian Hospital of Traditional Chinese Medicine, Liaoning, Dalian, 116000

语种 英文
文献类型 研究性论文
ISSN 1672-0415
学科 肿瘤学
基金 Supported by Special Funded Projects of the TCM Industry ;  国家自然科学基金 ;  Beijing Natural Science Fund
文献收藏号 CSCD:6595063

参考文献 共 23 共2页

1.  Bray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2018,68:394-424 被引 4310 次    
2.  Chen W Q. Cancer statistics in China, 2015. CA Cancer J Clin,2016,66:115-132 被引 643 次    
3.  Buffoni L. Adjuvant therapy of resected non-small cell lung cancer: can we move forward?. Curr Treat Options Oncol,2016,17:54 被引 2 次    
4.  Ettinger D S. Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw,2017,15:504-535 被引 92 次    
5.  Kay F U. Revisions to the tumor, node, metastasis staging of lung cancer (8th ed): rationale, radiologic findings and clinical implications. World J Radiol,2017,9:269-279 被引 7 次    
6.  Arriagada R. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med,2004,350:351-360 被引 84 次    
7.  Liu J. Comprehensive Treatment with Chinese Medicine in Patients with Advanced Non-Small Cell Lung Cancer: A Multicenter, Prospective, Cohort Study. Chin J Integr Med,2017,23:733-739 被引 7 次    
8.  Bing Z. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. BMC Complement Altern Med,2018,18:293 被引 5 次    
9.  Zhao X. Traditional Chinese medicine integrated with chemotherapy for stage ii-iiia patients with non-small-cell lung cancer after radical surgery: a retrospective clinical analysis with small sample size. Evid Based Complement Alternat Med,2018,2018:4369027 被引 2 次    
10.  Jiao L. Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep,2017,7:46524 被引 6 次    
11.  Li D R. Traditional Chinese medicines Yifei Qinghua Ointment prolongs the survival of patients with non-small cell lung cancer. Chin J Chin Oncol Rehabil (Chin),2017,14:651-655 被引 1 次    
12.  Hou C. In Vitro and in vivo inhibitory effect of Gujin Xiaoliu Tang in non-small cell lung cancer. Evid Based Complement Alternat Med,2018,2018:8936108 被引 2 次    
13.  American Joint Committee on Cancer. AJCC Cancer Staging Manual,2002:167-177 被引 2 次    
14.  Lin H S. Clinical practice guidelines of Chinese medicine in oncology,2016:44-56 被引 2 次    
15.  Brookmeyer R. A confidence interval for median survival time. Biometrics,1982,38:29-41 被引 5 次    
16.  Zeng Q. A Nomogram based on Inflammatory factors C-reactive protein and fibrinogen to predict the prognostic value in patients with resected non-small cell lung cancer. J Cancer,2017,8:744-753 被引 3 次    
17.  Liang Y. Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). J Translat Lung Cancer Res,2013,2:403-410 被引 4 次    
18.  Guo X W. Shenyi Capsule (参一胶囊)plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses. Chin J Integr Med,2018,24:227-231 被引 2 次    
19.  Yamamoto K. Effects of shakuyakukanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol,2001,81:333-334 被引 3 次    
20.  Johnson S B. Use of alternative medicine for cancer and its impact onsurvival. J Natl Cancer Inst,2018,200:688-690 被引 1 次    
引证文献 4 篇

1 王学谦 中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究 中医杂志,2020,61(8):690-694
被引 12 次

2 林奕 中医优势病种评价的方法学探讨 中医杂志,2021,62(19):1663-1667
被引 5 次

显示所有4篇文献

论文科学数据集
PlumX Metrics
相关文献

 作者相关
 关键词相关
 参考文献相关

版权所有 ©2008 中国科学院文献情报中心 制作维护：中国科学院文献情报中心
地址：北京中关村北四环西路33号 邮政编码：100190 联系电话：(010)82627496 E-mail:cscd@mail.las.ac.cn 京ICP备05002861号-4 | 京公网安备11010802043238号